Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.